Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Biogen Inc. (BIIB)

257.01   -0.82 (-0.32%) 09-29 16:00
Open: 258.53 Pre. Close: 257.83
High: 259.23 Low: 255.25
Volume: 887,332 Market Cap: 37,221(M)

Technical analysis

as of: 2023-09-29 4:26:10 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 307.62     One year: 315.94
Support: Support1: 251.85    Support2: 209.53
Resistance: Resistance1: 263.37    Resistance2: 270.5
Pivot: 257.12
Moving Average: MA(5): 257.08     MA(20): 258.72
MA(100): 279.62     MA(250): 281.06
MACD: MACD(12,26): -2.5     Signal(9): -2.9
Stochastic oscillator: %K(14,3): 51.1     %D(3): 45.5
RSI: RSI(14): 42.4
52-week: High: 319.76  Low: 250.3
Average Vol(K): 3-Month: 1,013 (K)  10-Days: 771 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BIIB ] has closed above bottom band by 48.4%. Bollinger Bands are 63.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 259.83 - 261.11 261.11 - 262.15
Low: 251.68 - 253.43 253.43 - 254.86
Close: 254.56 - 257.21 257.21 - 259.36

Company Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Headline News

Fri, 29 Sep 2023
FDA Approves Biogen's TOFIDENCE™ (tocilizumab-bavi), a ... - Biogen

Fri, 29 Sep 2023
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Uncommon Cents ... - MarketBeat

Thu, 28 Sep 2023
First Week of November 17th Options Trading For Biogen (BIIB) - Nasdaq

Tue, 26 Sep 2023
Biogen Inc. stock outperforms market on strong trading day - MarketWatch

Tue, 26 Sep 2023
Biogen Completes Acquisition of Reata Pharmaceuticals | Biogen - Biogen

Mon, 25 Sep 2023
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should ... - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. 145 (M)
Shares Float 144 (M)
% Held by Insiders 0.6 (%)
% Held by Institutions 90.8 (%)
Shares Short 3,140 (K)
Shares Short P.Month 3,420 (K)

Stock Financials

EPS 18.22
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 99.91
Profit Margin (%) 26.7
Operating Margin (%) 26.2
Return on Assets (ttm) 6.5
Return on Equity (ttm) 20.2
Qtrly Rev. Growth -5.1
Gross Profit (p.s.) 54.55
Sales Per Share 68.84
EBITDA (p.s.) 21.33
Qtrly Earnings Growth -43.8
Operating Cash Flow 1,430 (M)
Levered Free Cash Flow 1,710 (M)

Stock Valuations

PE Ratio 14.09
PEG Ratio 33.5
Price to Book value 2.57
Price to Sales 3.73
Price to Cash Flow 26.02

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.